TUXEDO-1

NCT04752059 📎

Regimen

Experimental
Trastuzumab deruxtecan (T-DXd) 5.4 mg/kg IV every 3 weeks (single-arm).
Control
N/A (single-arm).

Population

HER2-positive metastatic breast cancer with new or progressive brain metastases after prior HER2-directed therapy; intracranial-only primary endpoint trial.

Key finding

TUXEDO-1 was the first dedicated trial showing T-DXd achieves a ~73% intracranial response rate in HER2+ brain metastases. Supports T-DXd as an option for symptomatic CNS disease. Small N limits definitive conclusions but signal is strong.

Source: PMID 35941372

Timeline

  • Publication: 2022 Sep

Guideline citations

  • NCCN BREAST